Ovid Therapeutics to Present at Two Investor Healthcare Conferences in September 2018
NEW YORK, Aug. 29, 2018 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced that the company will present at two upcoming investor conferences:
- Baird’s 2018 Global Healthcare Conference
The company will participate in a fireside chat on Thursday, September 6, 2018 at 2:35 p.m. ET. The conference will be held at the InterContinential New York Barclay Hotel.
- BioCentury’s 25th Annual Newsmakers in the Biotech Industry Conference
The company will give a corporate presentation on Friday, September 7, 2018 at 11:00 a.m. ET. The conference will be held at the Millennium Broadway Hotel & Conference Center in New York, NY.
Live audio webcasts of the presentations can be accessed through the Events & Presentations section of the company's website at . Archived replays of the webcasts will be available on the company's website for two weeks following each live presentation.
About Ovid Therapeutics
Ovid Therapeutics (NASDAQ:OVID) is a New York-based biopharmaceutical company using its BoldMedicine™ approach to develop medicines that transform the lives of patients with rare neurological disorders. Ovid has a broad pipeline of first-in-class medicines. The company’s lead investigational medicine, OV101, is currently in development for the treatment of Angelman syndrome and Fragile X syndrome. Ovid is also developing OV935/TAK-935 in collaboration with Takeda Pharmaceutical Company Limited for the treatment of rare developmental and epileptic encephalopathies (DEE).
For more information on Ovid, please visit .
Contacts
Investors:
Lora Pike
Ovid Therapeutics Inc.
Senior Director, Investor Relations & Public Relations
Steve Klass
Burns McClellan, Inc
(212) 213-0006
Media:
Elliot Fox
W2O Group
(212) 257-6724
